SGLT2 Inhibitors May Have Clinical Benefits For Patients with Diabetes After Myocardial Infarction
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with a lower risk of major cardiovascular events or hospitalization for heart failure in...
